Clover Health Investments (NASDAQ:CLOV) Insider Sells 19,275 Shares of Company Stock

Clover Health Investments, Corp. (NASDAQ:CLOV) insider Karen Soares sold 19,275 shares of the firm’s stock in a transaction on Tuesday, October 20th. The shares were sold at an average price of $4.66, for a total transaction of $89,821.50. Following the completion of the transaction, the insider directly owned 1,573,423 shares of the company’s stock, valued at approximately $7,332,151.18. The trade was a 1.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Karen Soares also recently made the following trade(s):

• On Thursday, October 15th, Karen Soares sold 14,673 shares of Clover Health Investments stock. The shares were sold at an average price of $4.68, for a total transaction of $68,669.64.
• On Tuesday, September 15th, Karen Soares sold 6,846 shares of Clover Health Investments stock. The stock was sold at an average price of $4.78, for a total transaction of $32,723.88.

Clover Health Investments Trading Up 8.1%

Shares of Clover Health Investments stock traded up $0.36 during trading on Tuesday, hitting $4.80. The stock had a trading volume of 3,495,271 shares, compared to its average volume of 5,913,673. Clover Health Investments, Corp. has a 12 month low of $1.58 and a 12 month high of $5.59. The firm has a market cap of $2.55 billion, a price-to-earnings ratio of -95.98 and a beta of 2.45. The business’s 50-day moving average is $4.45 and its 200 day moving average is $4.03.

Clover Health Investments (NASDAQ:CLOV) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.01. The company had revenue of $743.17 million during the quarter, compared to analyst estimates of $728.27 million. Clover Health Investments had a negative return on equity of 4.20% and a negative net margin of 0.74%. As a group, equities analysts expect that Clover Health Investments, Corp. will post 0.06 EPS for the current year.

Analyst Ratings Changes

Several research firms have weighed in on CLOV. Zacks Research raised Clover Health Investments to a “hold” rating in a report on Monday, September 14th. Deutsche Bank Aktiengesellschaft began coverage on Clover Health Investments in a report on Thursday, September 10th. They set a “buy” rating and a $6.00 price objective for the company. Wall Street Zen cut shares of Clover Health Investments from a “strong-buy” rating to a “buy” rating in a research report on Sunday, August 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Clover Health Investments in a research report on Monday, September 21st. Finally, UBS Group raised their target price on shares of Clover Health Investments from $4.75 to $5.00 and gave the company a “neutral” rating in a research note on Thursday, August 6th. Two research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $4.75.

Trending Headlines about Clover Health Investments

Here are the key news stories impacting Clover Health Investments this week:

• Positive Sentiment: Clover Health earned top distinctions in U.S. News & World Report’s 2027 Medicare Advantage ratings across New Jersey, Georgia, and South Carolina. The recognition may strengthen the company’s brand, support member growth, and improve investor sentiment regarding its insurance operations. Clover Health Earns Top Honors in U.S. News & World Report’s 2027 Medicare Advantage Ratings Across Three States
• Positive Sentiment: Recent institutional activity was generally favorable. Bank of New York Mellon, Tidal Investments, and Winton Group initiated positions, while California State Teachers’ Retirement System and AXQ Capital increased their holdings. Such buying can reinforce confidence in CLOV’s longer-term outlook.
• Positive Sentiment: Analyst coverage includes Deutsche Bank’s “buy” rating and a $6.00 price target, above recent trading levels. Clover’s latest reported quarter also exceeded expectations for both earnings and revenue, although profitability remains limited.
• Neutral Sentiment: Analyst opinion remains mixed: the consensus rating is “Hold,” with two Buy, three Hold, and one Sell rating and an average price target of $4.75. This suggests optimism is present but not broad-based.
• Negative Sentiment: CEO Andrew Toy, CEO Conrad Wai, and insider Karen Soares sold shares at $4.68. The transactions were conducted under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards, and each insider retained a substantial stake, reducing the significance of the sales as a bearish signal. Clover Health Investments Insider Karen Soares Sells Shares

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. RFG Advisory LLC bought a new stake in Clover Health Investments during the first quarter worth about $35,000. Public Employees Retirement System of Ohio purchased a new position in shares of Clover Health Investments in the 2nd quarter worth about $42,000. Kestra Private Wealth Services LLC increased its position in shares of Clover Health Investments by 44.1% during the 1st quarter. Kestra Private Wealth Services LLC now owns 24,525 shares of the company’s stock valued at $43,000 after purchasing an additional 7,500 shares during the last quarter. Ballew Advisors Inc bought a new position in shares of Clover Health Investments during the 3rd quarter valued at about $44,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of Clover Health Investments during the 1st quarter valued at about $45,000. Institutional investors own 19.77% of the company’s stock.

About Clover Health Investments

Clover Health Investments, Corp. is a health insurance technology company focused on providing Medicare Advantage plans to eligible seniors in the United States. Its plans combine hospital, medical and prescription drug coverage with additional benefits that may vary by plan and location.

The company uses its Clover Assistant technology platform to provide physicians with data-driven insights intended to support clinical decision-making and care coordination. The platform aggregates member health information and helps participating providers identify care opportunities, manage chronic conditions and engage with patients.

Clover Health was founded in 2012 and became a publicly traded company in 2021 through a merger with a special purpose acquisition company.